Key facts
- Insilica CEO Dr. Thomas Luechtefeld co-authored a new paper.
- The paper is titled "Evidence-based AI: from trailblazer to trustblazer?".
- It was published in Frontiers in Artificial Intelligence.
- The framework aims to standardize high-stakes AI in toxicology.
Insilica Inc. announced the publication of a new perspective in the journal Frontiers in Artificial Intelligence, titled "Evidence-based AI: from trailblazer to trustblazer?". The paper was led by Insilica founder and CEO Dr. Thomas Luechtefeld. The publication introduces a new framework designed to standardize the use of artificial intelligence in high-stakes applications within the field of toxicology. The authors aim to guide the transition of AI in this critical area from an experimental 'trailblazer' stage to a more reliable and trusted 'trustblazer' status.